• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

金属蛋白酶组织抑制剂-1和-2与肥胖相关非酒精性脂肪性肝病:它们之间存在关联吗?

Tissue Inhibitors of Metalloproteinase-1 and 2 and Obesity Related Non-Alcoholic Fatty Liver Disease: Is There a Relationship.

作者信息

Abdelaziz Rokaya, Elbasel Mohamed, Esmat Serag, Essam Kareem, Abdelaaty Sahar

机构信息

Department of Internal Medicine, Cairo University, Cairo, Egypt.

出版信息

Digestion. 2015;92(3):130-7. doi: 10.1159/000439083. Epub 2015 Sep 1.

DOI:10.1159/000439083
PMID:26329758
Abstract

BACKGROUND/AIMS: Non-alcoholic fatty liver disease is a spectrum of clinical conditions, including simple steatosis and non-alcoholic steatohepatitis (NASH). The aim of the study is to evaluate the tissue inhibitors of metalloproteinase-1 and 2 (TIMPs) as noninvasive predictors of NASH.

METHODS

Three groups were included in the study. Obese patients (n = 30) with normal liver enzymes were included in group I and obese patients (n = 30) with elevated liver enzymes with liver biopsy-based diagnosis of NASH were included in group II. Age-matched subjects (n = 30) formed the control as group III. The lipid profile, liver enzyme levels and levels of TIMPs were compared among all the patients and subjects.

RESULTS

Comparison of groups I and II showed significantly elevated levels of TIMP-1 and TIMP-2 in group II as compared to group I (p < 0.05). Similarly, comparison between groups II and III showed significantly increased levels of TIMP-1 and TIMP-2 in group II as compared to group III (p < 0.05). TIMP-1 (sensitivity 96.7%, specificity 100%) and TIMP-2 (sensitivity 93.3%, specificity 100%) showed high accuracy in NASH diagnosis.

CONCLUSION

TIMP-1 and TIMP-2 may be considered noninvasive markers for the diagnosis of NASH.

摘要

背景/目的:非酒精性脂肪性肝病是一系列临床病症,包括单纯性脂肪肝和非酒精性脂肪性肝炎(NASH)。本研究的目的是评估金属蛋白酶组织抑制剂1和2(TIMPs)作为NASH的非侵入性预测指标。

方法

本研究纳入三组。第一组纳入肝功能正常的肥胖患者(n = 30),第二组纳入经肝活检诊断为NASH且肝功能酶升高的肥胖患者(n = 30)。年龄匹配的受试者(n = 30)作为第三组即对照组。比较所有患者和受试者的血脂谱、肝功能酶水平和TIMPs水平。

结果

第一组和第二组比较显示,与第一组相比,第二组的TIMP - 1和TIMP - 2水平显著升高(p < 0.05)。同样,第二组和第三组比较显示,与第三组相比,第二组的TIMP - 1和TIMP - 2水平显著升高(p < 0.05)。TIMP - 1(敏感性96.7%,特异性100%)和TIMP - 2(敏感性93.3%,特异性100%)在NASH诊断中显示出高准确性。

结论

TIMP - 1和TIMP - 2可被视为NASH诊断的非侵入性标志物。

相似文献

1
Tissue Inhibitors of Metalloproteinase-1 and 2 and Obesity Related Non-Alcoholic Fatty Liver Disease: Is There a Relationship.金属蛋白酶组织抑制剂-1和-2与肥胖相关非酒精性脂肪性肝病:它们之间存在关联吗?
Digestion. 2015;92(3):130-7. doi: 10.1159/000439083. Epub 2015 Sep 1.
2
[Determination and clinical significance of tissue inhibitors of metalloproteinase-1 and -2 in serum of children with nonalcoholic fatty liver disease].[非酒精性脂肪性肝病患儿血清金属蛋白酶组织抑制因子-1和-2的测定及其临床意义]
Zhongguo Dang Dai Er Ke Za Zhi. 2010 Jun;12(6):455-8.
3
[ASSESSMENT OF MATRIX METALLOPROTEINASES AND THEIR TISSUE INHIBITORS FOR NON-INVASIVE DIAGNOSIS OF LIVER FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE].[评估基质金属蛋白酶及其组织抑制剂用于非酒精性脂肪性肝病患者肝纤维化的无创诊断]
Eksp Klin Gastroenterol. 2016(7):25-31.
4
Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with nonalcoholic fatty liver disease.血清透明质酸水平和组织金属蛋白酶抑制剂-1与年龄相结合可预测非酒精性脂肪性肝病受试者试点队列中是否存在非酒精性脂肪性肝炎。
Transl Res. 2009 Oct;154(4):194-201. doi: 10.1016/j.trsl.2009.06.007. Epub 2009 Jul 14.
5
The value of different insulin resistance indices in assessment of non-alcoholic fatty liver disease in overweight/obese children.不同胰岛素抵抗指数在评估超重/肥胖儿童非酒精性脂肪性肝病中的价值。
Diabetes Metab Syndr. 2015 Apr-Jun;9(2):114-9. doi: 10.1016/j.dsx.2013.10.008. Epub 2013 Nov 14.
6
[The informative value of non-invasive liver fibrosis markers in patients with nonalcoholic fatty liver disease].[非侵入性肝纤维化标志物在非酒精性脂肪性肝病患者中的信息价值]
Ter Arkh. 2016;88(12):62-68. doi: 10.17116/terarkh2016881262-68.
7
Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.评估肥胖儿童和青少年体内的基质金属蛋白酶(MMP)-2、MMP-8、MMP-9及其抑制剂金属蛋白酶组织抑制剂(TIMP)-1和TIMP-2。
Clin Biochem. 2009 Jul;42(10-11):984-90. doi: 10.1016/j.clinbiochem.2009.03.025. Epub 2009 Apr 7.
8
Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis.血清微小RNA-122、-192和-21作为非酒精性脂肪性肝炎患者生物标志物的性能
PLoS One. 2015 Nov 13;10(11):e0142661. doi: 10.1371/journal.pone.0142661. eCollection 2015.
9
Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.绝经前肥胖女性体内的基质金属蛋白酶2和9及其组织抑制剂1和2:与心脏功能的关系
Int J Obes (Lond). 2008 May;32(5):763-71. doi: 10.1038/sj.ijo.0803794. Epub 2008 Jan 15.
10
Matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 and 2 as potential biomarkers for gestational hypertension.基质金属蛋白酶-9 和金属蛋白酶组织抑制剂 1 和 2 作为妊娠期高血压的潜在生物标志物。
Singapore Med J. 2012 Oct;53(10):681-3.

引用本文的文献

1
Lipid Storage, Lipolysis, and Lipotoxicity in Obesity.肥胖中的脂质储存、脂解和脂毒性。
Adv Exp Med Biol. 2024;1460:97-129. doi: 10.1007/978-3-031-63657-8_4.
2
Exploring non-invasive diagnostics for metabolic dysfunction-associated fatty liver disease.探索代谢功能障碍相关脂肪性肝病的非侵入性诊断方法。
World J Gastroenterol. 2024 Jul 28;30(28):3447-3451. doi: 10.3748/wjg.v30.i28.3447.
3
Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病无创生物标志物的进展
Metabolites. 2023 Oct 29;13(11):1115. doi: 10.3390/metabo13111115.
4
Prognostication in NAFLD: physiological bases, clinical indicators, and newer biomarkers.非酒精性脂肪性肝病的预测:生理基础、临床指标和新型生物标志物。
J Physiol Biochem. 2023 Nov;79(4):851-868. doi: 10.1007/s13105-022-00934-0. Epub 2022 Dec 6.
5
MCD Diet Rat Model Induces Alterations in Zinc and Iron during NAFLD Progression from Steatosis to Steatohepatitis.MCD 饮食大鼠模型在非酒精性脂肪性肝病从脂肪变性到脂肪性肝炎的进展过程中诱导锌和铁的改变。
Int J Mol Sci. 2022 Jun 19;23(12):6817. doi: 10.3390/ijms23126817.
6
Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches.非酒精性脂肪性肝病的诊断方法:从生化生物标志物到多组学无创方法
Diagnostics (Basel). 2022 Feb 4;12(2):407. doi: 10.3390/diagnostics12020407.
7
Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD.非酒精性脂肪性肝病的临床和分子生物标志物用于诊断和分期。
Int J Mol Sci. 2021 Nov 2;22(21):11905. doi: 10.3390/ijms222111905.
8
The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model.非甾体类法尼醇X受体激动剂西洛菲克改善大鼠非酒精性脂肪性肝炎模型的门静脉高压并减轻肝纤维化
Biomedicines. 2021 Jan 9;9(1):60. doi: 10.3390/biomedicines9010060.
9
Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis.非酒精性脂肪性肝炎中的诊断和介入循环生物标志物
Endocrinol Diabetes Metab. 2020 Aug 28;3(4):e00177. doi: 10.1002/edm2.177. eCollection 2020 Oct.
10
A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B.非酒精性脂肪性肝病与慢性乙型肝炎并存的一种新的地方病
Microorganisms. 2020 Oct 4;8(10):1526. doi: 10.3390/microorganisms8101526.